ANG Lifesciences India Ltd. () - Stock Overview & Analysis

Search your stocks

Profile

ang-lifesciences-indiaANG Lifesciences India Ltd.

₹35.5-1.17%

Market Cap

₹33.56 Cr

Stock P/E

-3.24

ROCE

0.46%

ROE

-12.48%

Book Value

₹58.41

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Others

Financials

YoY Net Sales

EPS Growth

Operating Margin

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Laggard

ANG Lifesciences India Ltd. is significantly underperforming its peers in the Pharmaceuticals & Drugs sector, characterized by negative revenue growth, earnings, and return on equity. In contrast, companies like Sun Pharmaceutical and Cipla stand out for their strong profitability and growth metrics, making them more attractive investments.

Key Points

• ANG Lifesciences has the lowest revenue growth (-33.55%) and EPS (-9.51).
• Sun Pharmaceutical leads with the highest revenue growth (8.42%) and EPS (45.55).
• Cipla shows robust profitability metrics with a 16.63% ROE and 13.59% ROA.
• ANG Lifesciences' high debt-equity ratio (0.91) positions it as financially stressed compared to its peers.

Top Performers

Sun Pharmaceutical Industries Ltd.

Highest revenue growth and EPS, indicating strong market performance and profitability.

Cipla Ltd.

Robust profitability with solid ROE and ROA metrics, alongside reasonable valuation.

Dr. Reddy's Laboratories Ltd.

Strong overall profitability metrics and low debt levels.